258 related articles for article (PubMed ID: 24105684)
81. Metastatic HER2-Positive Breast Cancer: Tailoring Treatment Un-'TIL' We Get It Right..
Jankowitz RC; Rastogi P
Oncology (Williston Park); 2016 Feb; 30(2):156, 158-9. PubMed ID: 26892152
[No Abstract] [Full Text] [Related]
82. Development and Challenges of the Discovery of HER2 Inhibitors.
Sun ZG; Zhao LH; Li ZN; Zhu HL
Mini Rev Med Chem; 2020; 20(20):2123-2134. PubMed ID: 32727326
[TBL] [Abstract][Full Text] [Related]
83. Signaling cross-talk in the resistance to HER family receptor targeted therapy.
Yamaguchi H; Chang SS; Hsu JL; Hung MC
Oncogene; 2014 Feb; 33(9):1073-81. PubMed ID: 23542173
[TBL] [Abstract][Full Text] [Related]
84. Targeting lipid metabolism is an emerging strategy to enhance the efficacy of anti-HER2 therapies in HER2-positive breast cancer.
Ligorio F; Pellegrini I; Castagnoli L; Vingiani A; Lobefaro R; Zattarin E; Santamaria M; Pupa SM; Pruneri G; de Braud F; Vernieri C
Cancer Lett; 2021 Jul; 511():77-87. PubMed ID: 33961924
[TBL] [Abstract][Full Text] [Related]
85. Changing strategies for target therapy in gastric cancer.
Lee SY; Oh SC
World J Gastroenterol; 2016 Jan; 22(3):1179-89. PubMed ID: 26811656
[TBL] [Abstract][Full Text] [Related]
86. Clinical Potential of Human Epidermal Growth Factor Receptor 2 and Human Epidermal Growth Factor Receptor 3 Imaging in Breast Cancer.
Henry KE; Ulaner GA; Lewis JS
PET Clin; 2018 Jul; 13(3):423-435. PubMed ID: 30100080
[TBL] [Abstract][Full Text] [Related]
87. HER3 and its Ligand, Heregulin, as Targets for Cancer Therapy.
Kawakami H; Yonesaka K
Recent Pat Anticancer Drug Discov; 2016; 11(3):267-74. PubMed ID: 27086600
[TBL] [Abstract][Full Text] [Related]
88. Regulation of ERBB3/HER3 signaling in cancer.
Mujoo K; Choi BK; Huang Z; Zhang N; An Z
Oncotarget; 2014 Nov; 5(21):10222-36. PubMed ID: 25400118
[TBL] [Abstract][Full Text] [Related]
89. The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer.
Hsu JL; Hung MC
Cancer Metastasis Rev; 2016 Dec; 35(4):575-588. PubMed ID: 27913999
[TBL] [Abstract][Full Text] [Related]
90. Translating gastric cancer genomics into targeted therapies.
Ang YL; Yong WP; Tan P
Crit Rev Oncol Hematol; 2016 Apr; 100():141-6. PubMed ID: 26947813
[TBL] [Abstract][Full Text] [Related]
91. [Targeted therapy: what does it mean? A physician point of view].
Spano JP
Bull Cancer; 2007; 94(7 Suppl):F111-4. PubMed ID: 17964988
[TBL] [Abstract][Full Text] [Related]
92. Cardio-oncology Related to Heart Failure: Epidermal Growth Factor Receptor Target-Based Therapy.
Kenigsberg B; Jain V; Barac A
Heart Fail Clin; 2017 Apr; 13(2):297-309. PubMed ID: 28279416
[TBL] [Abstract][Full Text] [Related]
93. Current and future biomarkers in gastric cancer.
Abbas M; Faggian A; Sintali DN; Khan GJ; Naeem S; Shi M; Dingding C
Biomed Pharmacother; 2018 Jul; 103():1688-1700. PubMed ID: 29864959
[TBL] [Abstract][Full Text] [Related]
94. Predictive biomarker candidates for the response of gastric cancer to targeted and cytotoxic agents.
Kim HK; Green JE
Pharmacogenomics; 2014 Feb; 15(3):375-84. PubMed ID: 24533716
[TBL] [Abstract][Full Text] [Related]
95. Human epidermal growth factor (Her-2) in gastric and colorectal adenocarcinoma.
Shabbir A; Qureshi MA; Mirza T; Khalid AB
J Pak Med Assoc; 2017 Jul; 67(7):1085-1090. PubMed ID: 28770892
[TBL] [Abstract][Full Text] [Related]
96. Update on HER-2 as a target for cancer therapy: intracellular signaling pathways of ErbB2/HER-2 and family members.
Olayioye MA
Breast Cancer Res; 2001; 3(6):385-9. PubMed ID: 11737890
[TBL] [Abstract][Full Text] [Related]
97. Molecular Targeting of the Human Epidermal Growth Factor Receptor-2 (HER2) Genes across Various Cancers.
Rubin E; Shan KS; Dalal S; Vu DUD; Milillo-Naraine AM; Guaqueta D; Ergle A
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256137
[TBL] [Abstract][Full Text] [Related]
98. Update on a tumor-associated NADH oxidase in gastric cancer cell growth.
Cheng HL; Lee YH; Yuan TM; Chen SW; Chueh PJ
World J Gastroenterol; 2016 Mar; 22(10):2900-5. PubMed ID: 26973386
[TBL] [Abstract][Full Text] [Related]
99. Gastric cancer: somatic genetics as a guide to therapy.
Zhang XY; Zhang PY
J Med Genet; 2017 May; 54(5):305-312. PubMed ID: 27609016
[TBL] [Abstract][Full Text] [Related]
100. Clinicopathologic features and treatment advances in cancers with HER2 alterations.
Cen S; Liu Z; Pan H; Han W
Biochim Biophys Acta Rev Cancer; 2021 Dec; 1876(2):188605. PubMed ID: 34358635
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
